Related Experiment Videos
L-arginine improves dystrophic phenotype in mdx mice
Vincent Voisin1, Catherine Sébrié, Stéfan Matecki
1Laboratoire de Neurobiologie Cellulaire et Moléculaire, CNRS UPR 9040, Avenue de la Terrasse, 91198 Gif sur Yvette Cedex, France.
Neurobiology of Disease
|September 3, 2005
Summary
L-arginine treatment increased utrophin levels and reduced muscle necrosis in mouse models of Duchenne muscular dystrophy. This suggests nitric oxide pathway activators may offer a realistic therapeutic strategy for muscular dystrophies.
Area of Science:
- Muscle Physiology
- Pharmacology
- Biochemistry
Background:
- Duchenne muscular dystrophy (DMD) is characterized by dystrophin deficiency.
- Utrophin upregulation is a potential therapeutic strategy to compensate for dystrophin loss.
- Nitric oxide (NO) pathway modulation, using L-arginine, has shown promise in increasing utrophin levels.
Purpose of the Study:
- To evaluate the therapeutic benefits of L-arginine in mdx mice, an animal model for DMD.
- To assess the impact of NO pathway activation on muscle pathology and function.
Main Methods:
- Administration of L-arginine to mdx mice.
- Magnetic resonance imaging (MRI) and histological staining to assess muscle necrosis.
- Measurement of creatine kinase levels.
- Quantification of utrophin and beta-dystroglycan expression.
- Assessment of diaphragm muscle isometric tension.
- Evaluation of Evans blue dye incorporation.
Main Results:
- L-arginine treatment led to a 35% reduction in necrotic zones in lower limb muscles.
- Serum creatine kinase levels decreased by 57%, and utrophin levels increased 2- to 3-fold.
- Beta-dystroglycan relocalized to the sarcolemma with utrophin.
- Diaphragm muscle function improved, with a 30% increase in isometric tension and reduced collagen and lipid accumulation.
- Molsidomine, another NO donor, also attenuated the dystrophic phenotype.
Conclusions:
- Pharmacological activation of the NO pathway, via L-arginine or other NO donors, shows significant therapeutic potential.
- This approach may offer a realistic treatment strategy for Duchenne and Becker muscular dystrophies by compensating for dystrophin deficiency.